




RealRate

PHARMACEUTICAL 2017

Avadel Pharmaceuticals PLC
Rank 226 of 308



The relative strengths and weaknesses of Avadel Pharmaceuticals PLC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avadel Pharmaceuticals PLC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Avadel Pharmaceuticals PLC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 129% points.

The company's Economic Capital Ratio, given in the ranking table, is 163%, being 82% points below the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	181,186
Cost of Goods Sold	13,248
Intangible Assets	41,328
Liabilities, Current	62,421
Liabilities, Non-Current	5,822
Other Assets	19,648
Other Compr. Net Income	-908
Other Expenses	102,242
Other Liabilities	135,170
Other Net Income	2,758
Other Revenues	150,246
Property and Equipment	3,320
Research and Development	34,611
Selling, General and Administrative Expense	44,179

Output Variable	Value in 1000 USD
Assets	245,482
Liabilities	203,413
Expenses	194,280
Revenues	150,246
Stockholders Equity	42,069
Net Income	-41,276
Comprehensive Net Income	-41,730
BaseVar	398,544
ECR before LimitedLiability	22%
Economic Capital Ratio	163%